

Cellestia: Targeting Transcription Factors for treating human cancers and auto immune and inflammatory diseases.

Charlotte Urech, Michele Vigolo, Florian Vogl, Dorian Fabbro and Rajwinder Lehal

Cellestia Biotech is a Basel based company focused on targeting Transcription Factors (TFs) implicated in human diseases. Currently the Cellestia platform is based on more than a decade of research on its lead molecule CB-103 and follow-ups targeting the NOTCH TFs. The front-runner CB-103 is currently in phase I/II studies and has demonstrated enhanced selectivity and safety in targeting NOTCH TFs gain of function in cancer. Targeting dysregulated TFs are expected to selectively inhibit downstream-signalling with minimal toxicities.

Cellestia is expanding the targeting of dysregulated NOTCH TFs to auto-immune and inflammatory diseases using a rich pipeline of CB-103 follow ups. In addition, Cellestia has launched additional programs to target oncogenic MYB as well as oncoviral TFs for the treatment of human cancers.

We will present a clinical update on CB-103 and the pre-clinical discovery programs targeting dysregulated NOTCH TFs in auto-immune and inflammatory diseases as well as novel approaches to various oncogenic TFs.